|
|
Post by liane on May 15, 2020 20:24:06 GMT -5
Tweets from Vdex are in the Vdex social media thread. I'd like to keep this thread more for news events as directly pertains to Afrezza and MNKD.
|
|
|
|
Post by falconquest on May 15, 2020 22:00:29 GMT -5
Tweets from Vdex are in the Vdex social media thread. I'd like to keep this thread more for news events as directly pertains to Afrezza and MNKD. liane, Doesn't pretty much everything Vdex does pertain to Mannkind since that is there target product? How more relevant can it be?
|
|
|
|
Post by cretin11 on May 19, 2020 3:24:59 GMT -5
Gotta agree with falcon. MNKD currently has one product. VDEX exists to sell that same product. VDEX success = MNKD success. Thank you sports for all the posts you have done on this topic. Thank you Liane for the thankless job you do to moderate this board. I don’t doubt your good intentions though I don’t agree with this particular decision.
|
|
|
|
Post by mnholdem on May 19, 2020 6:27:52 GMT -5
I don't understand the confusion. It's not like the administrator moved the thread to Off-Topics, where it would only be viewable to members. She simply moved a thread entitled Vdex Social Media Comments to the Afrezza in Blogs and Social Media folder of the main forum page. That folder was created specifically for social media posts about Afrezza.  |
|
|
|
Post by hellodolly on Jul 17, 2020 19:00:20 GMT -5
Glad to see a letter from Bill suggesting that VDEX and MNKD work together and not against each other and that his efforts have basically gotten them nowhere. How old is that letter? I just saw it today.
|
|
|
|
Post by sportsrancho on Jul 17, 2020 19:48:36 GMT -5
This was written today in answer to some of the HfM/shareholders emails to him.
7/17/2020
I have not disbanded the activist shareholder campaign, Hope for MannKind. I still believe shareholders need to push for change. I am also more convinced than ever that the company’s current marketing and sales strategy for Afrezza will ultimately fail. Unfortunately, with an unresponsive Board of Directors there is little we can do.
I have backed off my criticism of management and the Board because it really didn’t accomplish anything productive. Understandably, they circled the wagons and just resisted. We did not have the resources to overcome that. Also, in defense of management, the company faces a unique and abstruse problem. Given the nature of managers, it was unlikely they’d embrace radical change before exhausting the more conventional ideas. I can’t fault them for that. Lately, however, there are hopeful signs. Some of my recent interactions have led me to the conclusion that management would consider new and more unusual ideas. They seem more willing to listen to things they dismissed before.
It has always been clear that we all want the same thing: success for Afrezza and ultimately for patients. It seems circumstances are forcing us to the realization that maybe we need to work together rather than fight. I’m all for that. I believe we at Vdex understand both the problem and solution extremely well, likely better than management itself. As I’ve said before, Vdex sits at the nexus of patient, product, payer and prescriber. That’s a perspective few have. And, it’s the critical perspective to understand the intricacies of both problem and solution.
I remain steadfast in my belief in Afrezza. Nothing I have seen in hundreds of patients has changed my opinion that Al Mann was absolutely correct when he said that Afrezza was one of the greatest pharmaceutical products ever developed. That’s quite a statement. Few would really have the guts to say it, but if one really uses Afrezza properly for even a little while, you can come to no other conclusion. It’s just amazing.
We at Vdex will continue to do what we have always done: treat patients and expand our operation to treat more. Afrezza will remain at the center of our therapeutic arsenal. We would like to have a cooperative relationship with MannKind and we are open to a more constructive dialogue, but we will persevere even if we do not. Afrezza is too important to the world to let die.
Bill McCullough
Founder, Vdex Diabetes
Founder, Hope for MannKind
|
|
|
|
Post by mango on Jul 18, 2020 1:00:16 GMT -5
This was written today in answer to some of the HfM/shareholders emails to him. 7/17/2020 I have not disbanded the activist shareholder campaign, Hope for MannKind. I still believe shareholders need to push for change. I am also more convinced than ever that the company’s current marketing and sales strategy for Afrezza will ultimately fail. Unfortunately, with an unresponsive Board of Directors there is little we can do. I have backed off my criticism of management and the Board because it really didn’t accomplish anything productive. Understandably, they circled the wagons and just resisted. We did not have the resources to overcome that. Also, in defense of management, the company faces a unique and abstruse problem. Given the nature of managers, it was unlikely they’d embrace radical change before exhausting the more conventional ideas. I can’t fault them for that. Lately, however, there are hopeful signs. Some of my recent interactions have led me to the conclusion that management would consider new and more unusual ideas. They seem more willing to listen to things they dismissed before. It has always been clear that we all want the same thing: success for Afrezza and ultimately for patients. It seems circumstances are forcing us to the realization that maybe we need to work together rather than fight. I’m all for that. I believe we at Vdex understand both the problem and solution extremely well, likely better than management itself. As I’ve said before, Vdex sits at the nexus of patient, product, payer and prescriber. That’s a perspective few have. And, it’s the critical perspective to understand the intricacies of both problem and solution. I remain steadfast in my belief in Afrezza. Nothing I have seen in hundreds of patients has changed my opinion that Al Mann was absolutely correct when he said that Afrezza was one of the greatest pharmaceutical products ever developed. That’s quite a statement. Few would really have the guts to say it, but if one really uses Afrezza properly for even a little while, you can come to no other conclusion. It’s just amazing. We at Vdex will continue to do what we have always done: treat patients and expand our operation to treat more. Afrezza will remain at the center of our therapeutic arsenal. We would like to have a cooperative relationship with MannKind and we are open to a more constructive dialogue, but we will persevere even if we do not. Afrezza is too important to the world to let die. Bill McCullough Founder, Vdex Diabetes Founder, Hope for MannKind Really great letter and relieving to read. I can get behind this approach all day. Hope to see MannKind and Vdex working together someday soon. |
|
|
|
Post by babaoriley on Jul 18, 2020 1:39:39 GMT -5
I understand Bill is heading to the Middle East right after bringing VDEX and MannKind together! Go Bill!!!
|
|
|
|
Post by sportsrancho on Aug 25, 2020 14:17:07 GMT -5
|
|
|
|
Post by peppy on Aug 25, 2020 14:57:59 GMT -5
This is good. If we had health care insurance, to the moon. |
|
|
|
Post by sayhey24 on Aug 25, 2020 16:50:41 GMT -5
It would be good to see VDex partner with One Drop or Sugar IQ or Onduo, etc. Telemedicine is a good first step but it will be interesting to see how VDex will continue to use the Libre Pro in this environment. Hopefully its time they start using the Libre and Libreview.
|
|
|
|
Post by sportsrancho on Aug 25, 2020 18:37:50 GMT -5
Just FYI ..Almost all T1’s insurance covers Afrezza..we don’t have any problem. T2’s may be slightly harder.
It’s $150 for the telehealth appointment, then if insurance does not cover Afrezza they can get it from eagle pharmacy. We will work with them to get their blood sugar down and help them get approved after that.
|
|
|
|
Post by sugarland on Aug 25, 2020 19:42:30 GMT -5
|
|
|
|
Post by sugarland on Aug 25, 2020 19:42:58 GMT -5
Just FYI ..Almost all T1’s insurance covers Afrezza..we don’t have any problem. T2’s may be slightly harder. It’s $150 for the telehealth appointment, then if insurance does not cover Afrezza they can get it from eagle pharmacy. We will work with them to get their blood sugar down and help them get approved after that. Ditto! |
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 26, 2020 7:29:20 GMT -5
Sports, that's absolutely fantastic!!! What states is that available in now? If they will be rolling out to states gradually, please keep us posted with the progression as new states are added. If this works, this will be an incredible advance. |
|
